4.4 Review

The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis

Journal

JOURNAL OF MOLECULAR NEUROSCIENCE
Volume 66, Issue 4, Pages 617-628

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12031-018-1204-1

Keywords

Amyotrophic lateral sclerosis; MicroRNA; Epigenetics; Biomarker; Neurodegeneration

Funding

  1. The author(s) received no specific funding for this work [The author(s) received no specific funding for this work] Funding Source: Medline

Ask authors/readers for more resources

Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available